A 48-year-old woman from Bangalore with a history of invasive ductal carcinoma of the breast (T2N1M0, stage IIB) underwent modified radical mastectomy and chemotherapy 18 months ago. She has remained clinically well with no evidence of recurrence on imaging. Her baseline serum carcinoembryonic antigen (CEA) before surgery was 3.2 ng/mL (normal <2.5 ng/mL). During routine follow-up, her current CEA level is 8.5 ng/mL, and repeat imaging (CT chest/abdomen and bone scan) is negative for metastases. What is the most appropriate interpretation of this CEA elevation and the next clinical step?

Explanation

## CEA as a Tumor Marker in Breast Cancer: Interpretation and Clinical Strategy ### Role of CEA in Breast Cancer Surveillance **Key Point:** CEA is a non-specific tumor marker with limited sensitivity and specificity in breast cancer. Its primary value is in **serial monitoring** (trend analysis) rather than single-point diagnosis. **High-Yield:** CEA characteristics in breast cancer: - **Sensitivity:** 40–60% (many breast cancers do not produce CEA) - **Specificity:** Low; elevated in smoking, COPD, cirrhosis, inflammatory bowel disease, benign tumors - **Clinical utility:** Serial measurement (trend) > single absolute value - **Cutoff:** Generally >5 ng/mL is considered elevated, but baseline variation matters ### Interpretation of CEA Elevation in This Case | Finding | Interpretation | |---------|----------------| | CEA baseline 3.2 ng/mL (slightly elevated) | Possible occult disease or false positive | | CEA current 8.5 ng/mL | 2.6-fold rise from baseline | | Imaging (CT, bone scan) negative | No radiologically evident metastases | | Clinical status | Asymptomatic, well | | Correct next step | Serial CEA in 4–6 weeks | **Clinical Pearl:** A single CEA elevation does NOT confirm metastatic disease, especially when imaging is negative. The **trend** (rising CEA over time) is more predictive than an absolute value. ### Algorithm for CEA-Elevated Breast Cancer Survivor ```mermaid flowchart TD A[CEA elevation in breast cancer survivor]:::outcome --> B{Imaging negative?}:::decision B -->|Yes| C[Repeat CEA in 4-6 weeks]:::action C --> D{CEA rising further?}:::decision D -->|Yes| E[Consider PET-CT or MRI]:::action D -->|No| F[Likely false positive or benign cause]:::outcome B -->|No, metastases found| G[Metastatic recurrence confirmed]:::urgent G --> H[Palliative chemotherapy/targeted therapy]:::action ``` ### Why Serial Measurement Is Superior to Single Value **Mnemonic: "CEA Trend > CEA Level" = "T > L"** - **T**rend (rising CEA over months) = higher predictive value for recurrence - **L**evel (single absolute value) = low specificity, many false positives **High-Yield:** Studies show: - CEA doubling time <3 months = higher risk of recurrence - CEA rising in serial measurements = warrants advanced imaging (PET-CT, MRI) - Single CEA elevation with negative imaging = repeat in 4–6 weeks before escalating ### Causes of False-Positive CEA Elevation in Breast Cancer Survivors - **Smoking** (most common non-malignant cause) - **Chronic liver disease or cirrhosis** - **Inflammatory bowel disease (Crohn's, ulcerative colitis)** - **COPD or chronic respiratory disease** - **Benign colorectal or gastric polyps** - **Recent surgery or trauma** ### Why Other Options Are Incorrect Option 1 is premature — imaging is negative, so metastatic disease is not confirmed. Palliative chemotherapy without evidence of metastases is not justified. Option 3 is the CORRECT statement — serial CEA measurement is the appropriate next step. Option 4 is dangerous — CEA IS useful in breast cancer surveillance when used as a serial marker; ignoring a 2.6-fold rise from baseline is clinically negligent. [cite:Harrison 21e Ch 297; ASCO Guidelines on Tumor Markers in Breast Cancer]